rs751505742
Positions:
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM2
The NM_002047.4(GARS1):c.450T>A(p.Phe150Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: not found (cov: 32)
Consequence
GARS1
NM_002047.4 missense
NM_002047.4 missense
Scores
3
8
7
Clinical Significance
Conservation
PhyloP100: 0.200
Genes affected
GARS1 (HGNC:4162): (glycyl-tRNA synthetase 1) This gene encodes glycyl-tRNA synthetase, one of the aminoacyl-tRNA synthetases that charge tRNAs with their cognate amino acids. The encoded enzyme is an (alpha)2 dimer which belongs to the class II family of tRNA synthetases. It has been shown to be a target of autoantibodies in the human autoimmune diseases, polymyositis or dermatomyositis. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2015]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 2 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GARS1 | NM_002047.4 | c.450T>A | p.Phe150Leu | missense_variant | 4/17 | ENST00000389266.8 | NP_002038.2 | |
GARS1 | NM_001316772.1 | c.288T>A | p.Phe96Leu | missense_variant | 4/17 | NP_001303701.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GARS1 | ENST00000389266.8 | c.450T>A | p.Phe150Leu | missense_variant | 4/17 | 1 | NM_002047.4 | ENSP00000373918.3 | ||
GARS1 | ENST00000675651.1 | c.450T>A | p.Phe150Leu | missense_variant | 4/17 | ENSP00000502513.1 | ||||
GARS1 | ENST00000675810.1 | c.348T>A | p.Phe116Leu | missense_variant | 3/16 | ENSP00000502743.1 | ||||
GARS1 | ENST00000675693.1 | c.282T>A | p.Phe94Leu | missense_variant | 5/18 | ENSP00000502174.1 | ||||
GARS1 | ENST00000675051.1 | c.249T>A | p.Phe83Leu | missense_variant | 4/17 | ENSP00000502296.1 | ||||
GARS1 | ENST00000674815.1 | c.81T>A | p.Phe27Leu | missense_variant | 4/17 | ENSP00000502799.1 | ||||
GARS1 | ENST00000674851.1 | c.81T>A | p.Phe27Leu | missense_variant | 5/18 | ENSP00000502451.1 | ||||
GARS1 | ENST00000444666.6 | n.450T>A | non_coding_transcript_exon_variant | 4/18 | 3 | ENSP00000415447.2 | ||||
GARS1 | ENST00000674616.1 | n.*164T>A | non_coding_transcript_exon_variant | 5/18 | ENSP00000502408.1 | |||||
GARS1 | ENST00000674643.1 | n.450T>A | non_coding_transcript_exon_variant | 4/17 | ENSP00000501636.1 | |||||
GARS1 | ENST00000674737.1 | n.450T>A | non_coding_transcript_exon_variant | 4/18 | ENSP00000502464.1 | |||||
GARS1 | ENST00000674807.1 | n.450T>A | non_coding_transcript_exon_variant | 4/16 | ENSP00000502814.1 | |||||
GARS1 | ENST00000675529.1 | n.*320T>A | non_coding_transcript_exon_variant | 5/18 | ENSP00000501655.1 | |||||
GARS1 | ENST00000675859.1 | n.450T>A | non_coding_transcript_exon_variant | 4/15 | ENSP00000502033.1 | |||||
GARS1 | ENST00000676088.1 | n.*320T>A | non_coding_transcript_exon_variant | 5/19 | ENSP00000501884.1 | |||||
GARS1 | ENST00000676140.1 | n.450T>A | non_coding_transcript_exon_variant | 4/17 | ENSP00000502571.1 | |||||
GARS1 | ENST00000676164.1 | n.450T>A | non_coding_transcript_exon_variant | 4/17 | ENSP00000501986.1 | |||||
GARS1 | ENST00000676210.1 | n.450T>A | non_coding_transcript_exon_variant | 4/18 | ENSP00000502373.1 | |||||
GARS1 | ENST00000676403.1 | n.450T>A | non_coding_transcript_exon_variant | 4/16 | ENSP00000502681.1 | |||||
GARS1 | ENST00000674616.1 | n.*164T>A | 3_prime_UTR_variant | 5/18 | ENSP00000502408.1 | |||||
GARS1 | ENST00000675529.1 | n.*320T>A | 3_prime_UTR_variant | 5/18 | ENSP00000501655.1 | |||||
GARS1 | ENST00000676088.1 | n.*320T>A | 3_prime_UTR_variant | 5/19 | ENSP00000501884.1 | |||||
GARS1 | ENST00000676259.1 | n.428-48T>A | intron_variant | ENSP00000501980.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
GnomAD4 exome Cov.: 30
GnomAD4 exome
Cov.:
30
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
Bravo
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
Charcot-Marie-Tooth disease type 2 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 29, 2018 | This variant is not present in population databases (ExAC no frequency). This sequence change replaces phenylalanine with leucine at codon 150 of the GARS protein (p.Phe150Leu). The phenylalanine residue is highly conserved and there is a small physicochemical difference between phenylalanine and leucine. This variant has not been reported in the literature in individuals with GARS-related disease. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site, but this prediction has not been confirmed by published transcriptional studies. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The leucine amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Uncertain
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Uncertain
D
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D
M_CAP
Benign
D
MetaRNN
Uncertain
D
MetaSVM
Benign
T
PrimateAI
Pathogenic
D
PROVEAN
Pathogenic
D
REVEL
Uncertain
Sift
Uncertain
D
Sift4G
Benign
T
Polyphen
B
Vest4
MutPred
Loss of catalytic residue at F150 (P = 0.0622);
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at